Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Entrada Therapeutics (TRDA) Leases (2022 - 2025)

Entrada Therapeutics has reported Leases over the past 4 years, most recently at $60.5 million for Q4 2025.

  • Quarterly results put Leases at $60.5 million for Q4 2025, down 15.0% from a year ago — trailing twelve months through Dec 2025 was $60.5 million (down 15.0% YoY), and the annual figure for FY2025 was $60.5 million, down 15.0%.
  • Leases for Q4 2025 was $60.5 million at Entrada Therapeutics, down from $62.1 million in the prior quarter.
  • Over the last five years, Leases for TRDA hit a ceiling of $88.3 million in Q2 2023 and a floor of $14.2 million in Q1 2023.
  • Median Leases over the past 4 years was $67.1 million (2025), compared with a mean of $58.7 million.
  • Biggest five-year swings in Leases: plummeted 54.64% in 2023 and later surged 454.21% in 2024.
  • Entrada Therapeutics' Leases stood at $25.3 million in 2022, then surged by 221.59% to $81.5 million in 2023, then decreased by 12.73% to $71.1 million in 2024, then dropped by 15.0% to $60.5 million in 2025.
  • The last three reported values for Leases were $60.5 million (Q4 2025), $62.1 million (Q3 2025), and $65.7 million (Q2 2025) per Business Quant data.